Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

Documenti analoghi

• A tour of leukemia progress in 2025, viewed through the MD Anderson leukemia research lens
  di: Hagop M. Kantarjian, et al.
  Pubblicazione: (2025)
• Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups
  di: Alex Bataller, et al.
  Pubblicazione: (2024)
• A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS‐like tyrosine kinase 3 (FLT3)‐mutated acute myeloid leukemia
  di: Alexandre Bazinet, et al.
  Pubblicazione: (2025)
• A Phase 2 Trial of CPX‐351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2025)
• Cladribine With Low‐Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia
  di: Tapan M. Kadia, et al.
  Pubblicazione: (2026)